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ABSTRACT
Alternative mRNA splicing is a mechanism to
regulate protein isoform expression and is regulated
by alternative splicing factors. The alternative
splicing factor 45 (SPF45) is overexpressed in
cancer, although few biological effects of SPF45
are known, and few splicing targets have been
identified. We previously showed that Extracellular
Regulated Kinase 2 (ERK2) phosphorylation of
SPF45 regulates cell proliferation and adhesion to
fibronectin. In this work, we show that Cdc2-like
kinase 1 (Clk1) phosphorylates SPF45 on eight
serine residues. Clk1 expression enhanced,
whereas Clk1 inhibition reduced, SPF45-induced
exon 6 exclusion from Fas mRNA. Mutational
analysis of the Clk1 phosphorylation sites on SPF45
showed both positive and negative regulation of
splicing, with a net effect of inhibiting SPF45-
induced exon 6 exclusion, correlating with reduced
Fas mRNA binding. However, Clk1 enhanced SPF45
protein expression, but not mRNA expression,
whereas inhibition of Clk1 increased SPF45 degrad-
ation through a proteasome-dependent pathway.
Overexpression of SPF45 or a phospho-mimetic
mutant, but not a phospho-inhibitory mutant, stimu-
lated ovarian cancer cell migration and invasion,
correlating with increased fibronectin expression,
ERK activation and enhanced splicing and phosphor-
ylation of full-length cortactin. Our results demon-
strate for the first time that SPF45 overexpression
enhances cell migration and invasion, dependent
on biochemical regulation by Clk1.
INTRODUCTION
Alternative pre-mRNA splicing is an important molecular
mechanism for stimulating proteomic diversity. It has
been shown by combining mRNA-Seq and EST–cDNA
sequence data that alternative splicing occurs in 95% of
all human genes with multiple exons (1). Mutations
occurring at sites of pre-mRNA splicing significantly con-
tribute to the number of somatic mutations that are
known to occur in cancer and other genetic diseases
(2–4). Splicing is carried out by the spliceosome, a large
complex consisting of both small ribonuclear proteins and
other associated proteins (5). Both constitutive and alter-
native splicing are regulated by the serine/arginine-rich
(SR) protein family and the heterogeneous ribo-
nucleoprotein particles family of proteins, which have
antagonistic effects on splice site utilization (6–9), while
other splicing factors fall outside of these protein families.
Splicing factors are characterized by RNA recognition
motifs (RRMs), protein–protein interaction domains and
in the case of SR proteins, Arg-Ser (RS) rich motifs that
can become heavily phosphorylated on serine residues
(10). Alternative splicing site utilization by these RNA
binding proteins is dependent on their relative concentra-
tions, with increased expression enhancing their ability to
increase alternative pre-mRNA splicing (11). Differential
expression of alternative splicing factors has been
observed in cancer with the potential to profoundly
regulate protein diversity (12,13). Phosphorylation can
regulate protein–protein interactions within the
spliceosome as well as alternative splice site utilization
(14–17), and several kinases and phosphatases have been
identified that regulate phosphorylation of mRNA
splicing factors (18–21). Cdc2-like kinase 1 (Clk1) is a
nuclear kinase that has been shown to to be a major regu-
lator of several splicing factors, phosphorylating them on
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multiple serine residues and regulating their intranuclear
localization and splice site utilization on pre-mRNA
(19,20,22–24). Once the splicesome machinery is
assembled, dephosphorylation of splicing proteins can be
required for the catalytic process of splicing (25–27).
Splicing factor 45 (SPF45) was first identified in mam-
malian cells as a member of the spliceosome complex (28).
The SPF45 protein consists of an unstructured N-terminal
domain, followed by an a-helical G-patch motif (29)
involved in protein–protein (30) and protein–nucleic acid
interactions (31,32), and a C-terminal RRM domain
required for mRNA splicing (33). In mammalian cells,
SPF45 regulates splicing of Fas exon 6, which encodes
the transmembrane domain of this death receptor (33),
and exon 6 exclusion generates a secreted dominant-
negative Fas protein (34). SPF45 overexpression induces
inclusion of the extra domain A (EDA) region into mature
fibronectin transcripts, regulating cell adhesion to
fibronectin (21). SPF45 expression is low in normal
tissues, but is overexpressed in several forms of cancer,
including breast, ovarian and prostate (35). Stable
overexpression of SPF45 in HeLa cervical cancer cells
and in A2780 ovarian cancer cells was reported to
induce multidrug resistance (35,36).
We recently reported that SPF45 is a substrate for the
ERK, Jun N-terminal Kinase (JNK) and p38 MAP
kinases in response to extracellular stimulation, regulating
SPF45 splice site utilization, ovarian cancer cell prolifer-
ation and cell adhesion to fibronectin (21). In this study,
we investigated whether the SR protein kinase Clk1 plays
a role in the regulation of human SPF45. We demonstrate
that Clk1 directly phosphorylated SPF45 in vitro on eight
serine residues, stabilized SPF45 protein levels and
regulated SPF45-induced exon 6 skipping in Fas
pre-mRNA. Moreover, we found that SPF45 over-
expression induced cell migration and invasion in
ovarian cancer cells, fibronectin expression and splicing
and phosphorylation of the actin regulatory protein
cortactin, all of which were dependent on the identified
Clk1 phosphorylation sites. These data identify novel bio-
chemical and biological functions of SPF45 that are
governed by Clk1 phosphorylation.
MATERIALS AND METHODS
Plamids and siRNA
SPF45 and Clk1 mutants were generated using the
GeneTailorTM site-directed mutagenesis kit (Invitrogen,
Carlsbad, CA). The Fas minigene was generated using
genomic DNA from immortalized ovarian surface
epithelial (IOSE) cells as described previously (14). Clk1
plasmid was purchased from Addgene (Cambridge, MA).
Clk1 siRNA, control siRNA and SPF45 siRNA were
from Invitrogen.
Cell culture and transfection
COS-1, HeLa and SKOV-3 cells (American Type Culture
Collection, Manassas, VA) were grown in Dulbecco’s
Modified Eagle medium (Thermo Scientific) (COS-1 and
HeLa) or McCoy’s 5A medium (SKOV-3 and ES-2)
(Sigma, St. Louis, MO). A2780, OV2008 and OVCAR5
cells were grown in RPMI1640 medium (Sigma). All
media was supplemented with 10% fetal bovine serum
(FBS) (PAA, Dartmouth, MA), and cells were grown at
37C with 5% CO2. Transient plasmid transfections were
performed using Lipofectamine 2000 and siRNA transfec-
tions with Lipofectamine RNAiMAX (Invitrogen).
SKOV-3-Myc-SPF45 and OV2008-Myc-SPF45 stable
cells were generated by retroviral transduction as
described previously (21). Cellular populations expressing
Myc-SPF45 were selected with 1.5 mg/ml puromycin for 2
weeks and maintained in 0.75mg/ml.
RT-PCR
Total RNA was extracted from cells using TRIzol
(Invitrogen). The cDNA was transcribed from 2 mg of
total RNA using a high capacity cDNA reverse transcrip-
tion kit (Applied Biosystems, Foster, CA). PCR was per-
formed using a Mycycler thermal cycler (Bio-Rad,
Hurcules, CA) and analysed on agarose gels. Primer se-
quences are in Supplementary Table S1. Spliced products
were quantified using Gel-Pro Analyzer 3.1. Results were
expressed as a relative ratio, which was calculated by
comparing the ratios of the lower bands to the upper
bands in other groups with the ratio in the indicated
group, which was set to 1. Values are means±standard
error (SE) from three independent experiments performed
in duplicate. Quantitative real-time PCR was carried out
using either Taqman Gene Expression Assays:
Hs00269734_m1 for Clk1 and Hs99999901_sl for the
housekeeping gene of 18S RNA on a 7300 Real-Time
PCR System (Applied Biosystems) or Bio-Rad’s Sso-
AdvancedTM SYBR Green Supermix on an Eppendorf
(Hauppage, NY) Mastercycler Realplex 2. Quantification
was determined by Relative Quantification Software
(Applied Biosystems). Statistical comparisons of exon
exclusion were performed using analysis of variance
(ANOVA) followed by Fisher’s Protected Least Signifi-
cance Difference (PLSD). Values of all parameters were
considered significantly different at a value of P< 0.05.
Immunoprecipitations and western blotting
Cells were lysed in M2 lysis buffer (37), sonicated and
protein concentrations determined using the BCA kit
(Pierce, Rockford, IL). Typically, 25 mg of protein was
run on an SDS–PAGE gel and transferred to nitrocellu-
lose. For immunoprecipitations (IP), transfected cells were
lysed, and equal amounts of protein were immunopre-
cipitated with anti-Myc antibody (Sigma) conjugated to
protein G agarose (Roche), washed and the immunopre-
cipitates run on SDS–PAGE. Nitrocellulose membranes
were blocked in 5% bovine serum albumin and were
probed with antibodies overnight: anti-Myc, actin and
fibronectin antibodies (Sigma); anti-Clk1, SF1, SF3b155
and U2AF65 (Abcam, Cambridge, MA); anti-p-ERK and
cortactin (Cell Signaling); anti-cortactin (clone 4F11) (38),
cortactin p405 and cortactin p418 (39); anti-ERK
(Michael Weber, University of Virginia); and anti-
phospho-serine (Millipore). Polyclonal anti-SPF45
antibody was generated to recombinant His-SPF45
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protein in rabbits (Pacific Immunology, San Diego, CA).
Secondary antibodies conjugated to horseradish peroxid-
ase were followed by enhanced chemiluminescence
(Pierce). Results were confirmed by at least three inde-
pendent experiments.
In vitro kinase assay
Recombinant SPF45 proteins were prepared as described
previously (21). Recombinant, active Clk1 (Sigma) was
incubated with His-SPF45 or a His-SPF45 phosphoryl-
ation site mutant in 5mM MOPS, 2.5mM beta-
glycerophosphate, 1mM EGTA, 0.25mM EDTA, 5mM
MgCl2, 0.5mM dithiothreitol and 100 mM ATP.
Radioactive experiments contained 10 mCi [g-32 P]-ATP
per reaction. The samples were incubated at 30C for
30min before the reaction was stopped with 2
Laemmli sample buffer and run on SDS–PAGE.
Radioactive samples were transferred to nitrocellulose
and exposed for autoradiography. Gels containing
samples for mass spectrometry analysis were stained
with Coomassie stain, and SPF45 was excised from the
gel. After trypsin digest, samples were analysed via
liquid chromatography (LC)-electrospray ionization-
tandem mass spectrometry (MS/MS) on a linear ion
trap mass spectrometer (LTQ XL, Thermo Finnigan)
coupled to a Dionex Ultimate 3000 nano LC system.
Phosphorylation sites were confirmed by manual inspec-
tion of the data.
RNA immunoprecipitation
RNA immunoprecipitation (RIP) was performed as
described previously (40). Briefly, COS-1 cells were
cotransfected with Fas and either empty vector,
Myc-SPF45, Myc-SPF45-8A or Myc-SPF45-8D. Protein
G agarose beads pre-coated with anti-Myc monoclonal
antibody (Sigma) or isotype control IgG (Santa Cruz
Biotechnology, Santa Cruz, CA) in NET2 buffer
[50 mM Tris–HCl (pH 7.4), 150mM NaCl, 1mM
MgCl2, 0.05% Nonidet P-40, 10mM dithiothreitol
(DTT), 150mM EDTA, RNase OUTTM and Superase
INTM] were incubated briefly (5 s) with cell lysates. The
beads were quickly pelleted, an aliquot of lysate was
removed as input control and the beads were reintroduced
for immunoprecipitation of Myc-SPF45 at 4C. To
recover RNA from the RIP complexes, the washed
beads were re-suspended in 100ml of NET2 and 100 ml
of proteinase K (0.5mg/ml) buffer for 30min at 55C.
RNA was extracted with phenol-chloroform-isoamyl
alcohol and precipitated in the presence of glycogen. For
Fas RNA expression analysis, the RNA isolated from the
IP was subjected to quantitative RT-PCR (qRT-PCR).
Values were means±SD from six experiments.
Statistical analysis were performed by using ANOVA
followed by Fisher’s PLSD, where P< 0.05 was con-
sidered significant.
Cell migration and invasion
For wound-healing assays, confluent cultures of stable
SKOV-3 and OV2008 cell lines were scratched using a
10 ml of pipette tip. The culture medium and cell debris
were removed and replaced with fresh culture medium
containing 5 mg/ml mitomycin C. Cells were photographed
at the time of the scratch (0 h) and at 20 or 24 h, and the
percentage of wound closure was calculated using ImageJ
software. Values are means±SE from six experiments.
Statistical analysis were performed by using ANOVA
followed by Fisher’s PLSD, where P< 0.05 was con-
sidered significant. For transwell migration, stable
SKOV-3 cells (2 104 cells) or OV2008 cells (5 104
cells) in 200 ml of medium containing 0.1% FBS were
added to the upper chamber, and 400 ml of culture
medium with 10% FBS was added to the lower chamber
of a transwell dish (BD BiocoatTM, BD Biosciences,
Franklin Lakes, NJ). After 24 h, the non-migrated cells
were removed from the upper surface, and cells on the
underside of the membrane were fixed with 4%
paraformaldehyde and stained with 0.1% crystal violet.
Migrated cells from 10 fields were counted and photo-
graphed. Values were means±SE from six experiments.
Statistical analysis were performed by using ANOVA
followed by Fisher’s PLSD, where P< 0.05 was con-
sidered significant. For the cell invasion assays, 2 104
SKOV-3 cells or 5 104 OV2008 cells in 0.5ml of
culture medium containing 0.1% FBS were introduced
to the upper chamber of BD BiocoatTM GFR Matrigel
Invasion chamber (BD Biosciences, Franklin Lakes, NJ).
The lower chamber was filled with 750 ml of culture
medium with 10% FBS. Analysis of invading cells was
carried out as aforementioned.
RESULTS
Clk1 promotes SPF45-induced exon 6 exclusion
SPF45 enhances exon 6 exclusion from Fas pre-mRNA in
a cellular minigene assay (21,33). To determine whether
endogenous SPF45 has a similar effect on splicing of en-
dogenous Fas pre-mRNA, we transfected SKOV-3
ovarian cancer cells with siRNA against SPF45.
Seventy-two hour after transfection, RNA was harvested,
and the endogenous Fas mRNA isoforms containing or
excluding exon 6 were analysed by RT-PCR using primers
flanking exon 6. SPF45 knockdown inhibited the splicing
of the short Fas mRNA isoform (lacking exon 6) from Fas
mRNA (Figure 1A). No other bands were detected on the
gel. Immunoblotting of parallel cultures with an
anti-SPF45 polyclonal antibody confirmed SPF45
knockdown (Figure 1B). This polyclonal antibody
generated to recombinant SPF45 protein recognizes en-
dogenous SPF45 from several ovarian cancer cell lines
and HeLa cells, with specificity determined by comparison
with lysate from COS-1 cells transfected with untagged
SPF45 (COS-1+con) and SPF45 shRNA knockdown in
OV2008 cells (Figure 1C). Consistent with the above-
splicing results, transient transfection of SPF45 into
COS-1 cells increased splicing of the short isoform of en-
dogenous Fas mRNA, demonstrating enhanced exon 6
exclusion (Figure 1D). Clk1 is an SR protein kinase that
phosphorylates splicing factors to regulate their local-
ization and splice site utilization (19,20,22–24). To deter-
mine whether Clk1-regulated SPF45-dependent exon
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6 exclusion from endogenous Fas mRNA, COS-1
cells were cotransfected with Clk1 and SPF45.
Overexpression of Clk1 with SPF45 significantly increased
exon 6 exclusion from endogenous Fas mRNA compared
with transfection of SPF45 and empty vector (Figure 1D).
We used our previously described Fas minigene (14,21),
comprised of exon 5 through exon 7 of genomic Fas,
including introns (Figure 1E), to study the effect of Clk1
on SPF45 splice site utilization. Cotransfection of COS-1
cells with Fas and increasing amounts of Myc-SPF45
plasmid caused a dose-dependent increase in exon 6
exclusion, shown as an increase in the lower band,
demonstrating that our Fas minigene worked as a
target of SPF45 in cells (Figure 1F) (21). COS-1 cells
were chosen for minigene splicing assays owing to their
low expression of endogenous SPF45 (Figure 1C), which
allowed us to better determine SPF45-specific effects on
alternative splicing of Fas mRNA. Clk1 was co-
transfected into cells with SPF45 and the Fas minigene
and exon 6 exclusion of Fas was determined. Clk1
enhanced SPF45-induced exon 6 excluion of Fas by
>50% (Figure 1G), suggesting that SPF45 may be a
cellular target of Clk1. Interestingly, Clk1 overexpres-
sion also enhanced Myc-SPF45 protein expression
Figure 1. Clk1 enhances SPF45-induced exon 6 exclusion from Fas mRNA. (A) SKOV3 cells were transfected with siRNA against SPF45 (siSPF45)
or scrambled control siRNA (scr) for 72 h, and RNA was isolated. Endogenous Fas spliced isoforms were analysed by RT-PCR using primers
flanking exon 6. PCR products representing mRNA including exon 6 [Fas (L)] and excluding exon 6 [Fas (S)] are shown and are quantified in the
graph, with the ratio Fas (S) to Fas (L) set to one in the control siRNA group. The resuslts are from three independent experiments performed in
duplicate and were statistically significant. (B) Parallel cultures to those in (A) were lysed for western blotting using antibodies to SPF45 and actin.
(C) Cell lysates from the indicated cell lines were immunoblotted for SPF45 using a polyclonal antibody to recombinant His-SPF45. COS-1 cells
transfected with untagged SPF45 (COS-1, +con) and OV2008 cells expressing control or SPF45-specific shRNA served as positive controls. The
SPF45 band (SPF45) and an SPF45 degradation product (degr.) in the positive control lane are labelled. (D) COS-1 cells were cotransfected with
Myc-SPF45 (0.6 mg) and Clk1 (0.8 mg) and endogenous Fas spliced products were analysed by RT-PCR 24 h after transfection. A representative gel is
shown. The means and SE for the relative ratio of exon 6 exclusion from three experiments done in duplicate are shown under the gel images.
(E) Schematic of the Fas minigene splicing reporter used in transfection assays and the different mRNA isoforms derived from it, representing
inclusion or exclusion of exon 6. (F) SPF45 expression induced exon 6 exclusion in a dose-dependent manner. COS-1 cells were co-transfected with
Fas and increasing amounts of Myc-SPF45. Total RNA was extracted at 24 h and analysed by RT-PCR using Fas-specific primers. A
representaive gel from at least three independent experiments is shown, and the ratio of the lower band to the upper band is shown below the
gel. The lower panel represents a western blot of Myc-SPF45 and actin protein expression from one experiment. (G) Clk1 overexpression promotes
SPF45 alternative splicing activity. COS-1 cells were cotransfected with Fas (0.3 mg), Myc-SPF45 (0.6 mg) and Clk1 (0.8 mg), and spliced products
were analysed by RT-PCR 24 h after transfection. A representative gel is shown. The means and SE for the relative ratios of exon 6 exclusion are
shown under the gel images. Results were derived from three independent experiments done in duplicate. Statistical significance (P< 0.01) is indicated
in the graph. (H) Clk1 overexpression enhanced SPF45 protein levels. Protein lysates were prepared from cells transfected as in (G) and were
subjected to western blotting using antibodies to Myc, Clk1 and actin.
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(Figure 1H). As SPF45 concentration directly affects
splice site utilization (Figure 1F), the enhancement of
SPF45 expression by Clk1 could be a possible mechanism
for the enhanced exon 6 exclusion and was investigated
futher.
Clk1 inhibition prevents exon 6 exclusion by SPF45
To further determine the role of Clk1 kinase activity in
regulating SPF45 exon 6 exclusion of Fas pre-mRNA, we
generated a kinase-dead Clk1, Clk1-K233R, and
co-transfected COS-1 cells with plasmids for SPF45 and
Fas. Clk1-K233R decreased both SPF45-induced exon 6
exclusion (Figure 2A) and SPF45 protein levels
(Figure 2B) compared with wild-type Clk1. To confirm
this result, a selective Clk1 inhibitor, TG003 (41), was
used to block endogenous Clk1 activity. TG003 not only
inhibited the increase of exon 6 exclusion induced by
SPF45 (Figure 2C) but also decreased SPF45 protein ex-
pression (Figure 2D), similar to what was seen with
kinase-dead Clk1 expression. Next, we used siRNA to
knock down endogenous Clk1 expression. Transfection
of cells with any of three different siRNA-targeting Clk1
led to a signifcant decrease in endogenous Clk1 mRNA
and protein levels after 48 h, as determined by real-time
PCR and western blot analysis, respectively (Figure 3A
and B). The siRNA-mediated knockdown of Clk1 in
COS-1 cells significantly decreased exon 6 exclusion
in an SPF45-dependent manner (Figure 3C and D)
and greatly inhibited Myc-SPF45 protein expression
(Figure 3E), most likely contributing to the reduction in
exon 6 exclusion.
Inhibition of Clk1 decreases the half-life of SPF45
through a proteasome-dependent pathway
We suspected that the enhancement or inhibition of exon 6
exclusion by SPF45 with Clk1 activation or inhibition,
respectively, was partially due to regulation of SPF45
protein levels, as SPF45 expression directly impacts exon
6 exclusion (Figure 1F). To determine whether Clk1
regulated the half-life of SPF45, A2780 ovarian cancer
Figure 3. Knockdown of Clk1 decreases both SPF45 protein levels and
SPF45-induced exon 6 exclusion. (A) COS-1 cells were transfected with
three siRNA against Clk1 or scrambled control siRNA (scr). Total
RNA was extracted at 48 h post-transfection and was subjected to
real-time PCR analysis using primers specific to Clk1. (B) COS-1
cells were transfected as in (A), and whole-cell protein lysates were
immunoblotted with anti-Clk1 and anti-actin antibodies. (C) COS-1
cells were transfected with siRNA against Clk1 (siClk1-1, siClk1-2
and siClk1-3) or scrambled control siRNA for 48 h and then
cotransfected with plasmids for DFas and SPF45 or empty vector.
Twenty-four hour after plasmid transfection, mRNA was collected,
and Fas spliced products were analysed by RT-PCR. (D) Graph
showing the relative ratio of splicing products (the lower band to the
upper band) after quantification of the corresponding lanes in panel
(C). The ratio of splicing products for the scrambled siRNA in the
presence of transfected SPF45 was set to 1. The results are from
three independent experiments done in duplicate and statistical signifi-
cance (P< 0.01) is indicated. (E) COS-1 cells were transfected as in (C),
and whole-cell protein lysates were immunoblotted with anti-Myc and
anti-actin antibodies.
Figure 2. Inhibition of Clk1 decreases both SPF45 protein levels and
exon 6 exclusion by SPF45. (A) COS-1 cells were cotransfected with
Fas (0.3 mg), Myc-SPF45 (0.6 mg) and Clk1 (0.8 mg) or Clk1-K233R
(0.8 mg), and spliced products were analysed by RT-PCR 24 h after
transfection. A representative gel is shown. The graph under the gel
image represents the quantification of the corresponding bands from
three experiments done in duplicate. (B) COS-1 cells were cotransfected
as in (A), and whole-cell protein lysates were immunoblotted with
anti-Myc and anti-actin antibodies. (C) COS-1 cells were pretreated
with the Clk inhibitor TG003 (10 mM) for 1 h and then cotransfected
with Fas and Myc-SPF45 or empty vector. Twenty-four hour
post-transfection, spliced products were analysed by RT-PCR. A rep-
resentative gel is shown. A graph under the gel image showed the
relative ratio of the lower band to the upper band. The results were
derived from three independent experiments done in duplicate and stat-
istical significance (P< 0.01) is indicated. (D) COS-1 cells were pre-
treated with TG003 for 1 h and then cotransfected as in
(C). Whole-cell protein lysates were immunoblotted as in (B).
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cells, which express high levels of endogenous SPF45
(Figure 1C), were treated with cycloheximide in the
absence or presence of TG003 for 24 h (Figure 4A).
TG003 significantly decreased the half-life of endogenous
SPF45 from 15 to 8 h (Figure 4B). In addition, SKOV-3
ovarian cancer cells stably expressing Myc-SPF45 were
treated with DMSO or TG003 in the presence of
cycloheximide. Consistent with the aforementioned
results, TG003 decreased the half-life of Myc-SPF45
from 16 to 7 h (Figure 4C and D). Moreover, knockdown
of endogenous Clk1 with siRNA decreased endogenous
SPF45 protein levels in both SKOV-3 and HeLa cells
(Figure 4E). To determine whether the decrease in
SPF45 half-life in the presence of TG003 was dependent
on the proteasome, A2780 cells were treated with the pro-
teasome inhibitor MG132 in the absence or presence of
TG003 (Figure 4F). MG132 co-treatment with TG003
prevented the downregulation of SPF45 protein levels
that was induced by TG003 treatment, indicating that
Clk1 inhibition regulated SPF45 degradation through a
proteasome-dependent pathway.
Clk1 phosphorylates SPF45
The aforementioned data and the ability of Clk1 to
regulate splicing factors suggest that Clk1 may regulate
SPF45 through direct phosphorylation. To test this, we
performed an in vitro kinase assay with recombinant
Clk1, bacterially expressed histidine-tagged SPF45
(His-SPF45) and [g-32 P]-ATP and observed a robust
phosphorylation of SPF45 by Clk1 (Figure 5A). To deter-
mine the site(s) of phosphorylation, parallel reactions were
performed using unlabelled ATP, and the His-SPF45 was
excised from the subsequent Coomassie stained gel. Eight
serine phosphorylation sites were identified by (LC)-
electrospray ionization-tandem mass spectrometry
(MS/MS): serines 48, 62, 202, 204, 222, 266, 288 and 291
(Figure 5B). We generated single alanine mutants at S202
or S204 and observed reduced phosphorylation of each
mutant by Clk1 in vitro using [g-32P]-ATP (Figure 5C).
Mutation of six residues (serines 48, 62, 222, 266, 288 and
291; SPF45-6A) showed greatly reduced phosphorylation
by Clk1 in a radioactive in vitro kinase assay (Figure 5C),
and mutation of all eight sites to alanine (SPF45-8A)
blocked phosphorylated by Clk1 in vitro, demonstrating
that there were no additional Clk1 phosphorylation sites
on SPF45. When transfected into COS-1 cells, Myc-
SPF45-8A showed greatly reduced serine phosphorylation
compared with wild-type Myc-SPF45, demonstrating that
these sites are phosphorylated in cells (Figure 5D).
Effects of SPF45 phosphorylation site mutation on Fas
exon 6 exclusion
To determine the collective effect of Clk1 phosphorylation
on SPF45, we compared exon 6 exclusion by SPF45,
Figure 4. Clk1 inhibition decreases the half-life of SPF45 through a proteasome-dependent pathway. (A) A2780 cells were treated with cycloheximide
(50mg/ml) and TG003 (10mM) or DMSO for the indicated times, followed by western blot analysis with anti-SPF45 and anti-actin antibodies to detect
endogenous proteins. (B) Graph of SPF45 protein levels relative to the actin loading control from (A). (C) SKOV-3-Myc-SPF45 stable cells were treated
with cycloheximide and TG003 or DMSO for the indicated times followed by western blot analysis with anti-Myc and anti-actin antibodies. (D) Graph
of Myc-SPF45 protein levels relative to actin from (C). (E) Knockdown of Clk1 inhibits expression of endogenous SPF45. SKOV-3 cells and HeLa cells
were transfected with siRNA to Clk1 or control siRNA (scr) for 48h. Cell lysates were immunoblotted for endogenous Clk1, SPF45 and actin. (F) The
increased degradation of SPF45 with Clk1 inhibition is proteasome-dependent. A2780 cells were treated with MG132 (10mM) and TG003 or DMSO for
the indicated times, followed by western blot analysis with anti-SPF45 and anti-actin antibodies. Quantitation of SFP45 expression relative to actin is
below each lane, with the DMSO control lane set to 1.
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SPF45-8A or a phospho-mimetic SPF45-8D in the Fas
minigene assay. Surprisingly, Myc-SPF45-8A demo-
nstrated a significant 25% increase in exon 6 exclusion
compared with wild-type SPF45 in the absence of exogen-
ous Clk1, suggesting that phosphorylation of these sites in
total inhibited SPF45-induced exon 6 exclusion
(Figure 6A and B). Similarly, mutation of these eight
residues to aspartate inhibited exon 6 exclusion by a com-
parable amount. When Clk1 was co-expressed, wild-type
Myc-SPF45 induction of exon 6 was enhanced, as afore-
mentioned, but the significant difference between
wild-type Myc-SPF45 and Myc-SPF45-8A was lost, sug-
gesting that Clk1 had little effect on SPF45 exon 6 exclu-
sion when the 8 phosphorylation sites were mutated to
alanine. Similarly, Clk1 expression had little effect on
Myc-SPF45-8D-induced exon 6 exclusion. SPF45
mRNA expression was unaffected by Clk1 expression
(Figure 6C), whereas expression of the mutant proteins
was similar to wild-type (Figure 6D).
Clk1 phosphorylation sites in SPF45 differentially affect
exon 6 exclusion
To further determine whether each of the identified Clk1
phosphorylation sites on SPF45 exert the same effect on
SPF45 splice site utilization in Fas pre-mRNA, we
generated different combinations of alanine mutants and
tested their ability to induce exon 6 exclusion from Fas.
Both Myc-SPF45-S48/222/266A and Myc-SPF45-S48/62/
266A significantly increased exon 6 exclusion compared
with wild-type Myc-SPF45 (Figure 7A), whereas Myc-
SPF45-S48/202/204/266A, Myc-SPF45-S48/202/204/266/
288/291A and Myc-SPF45-S202/204/288/291A signifi-
cantly decreased exon 6 exclusion compared with wild-
type Myc-SPF45, suggesting that phosphorylation of
serines 48, 222 and 266 by Clk1 inhibited exon 6 exclusion
and phosphorylation of serines 202 and 204 promoted
exon 6 exclusion. To confirm this result, we made single
mutants of serines 48A, 62A, 222A and 266A and double
mutants of serine 202/204A and S288/291A. COS-1 cells
were transiently transfected with these mutants and
Myc-SPF45. The results showed that Myc-SPF45-S48A,
Figure 5. Clk1 phosphorylates eight serines in SPF45. (A) His-SPF45
was incubated in the absence or presence of recombinant CLK1 and
[g-32P]-ATP in an in vitro kinase assay. The reactions were run on a
gel, transferred to nitrocellulose and exposed for autoradiography,
followed by western blotting for SPF45. (B) Recombinant Clk1 was
used to phosphorylate His-SPF45 from bacteria in vitro, and the
phosphorylated protein was run on a gel and processed for mass spec-
trometry. Eight phosphorylated serine residues in SPF45 were identified.
(C) Recombinant Clk1 was used to phosphorylate His-SPF45,
His-SPF45-S202A, His-SPF45-S204A, His-SPF45-6A (S48/62/222/266/
288/291A) and His-SPF45-8A (S48/62/202/204/222/266/288/291A)
in vitro using [g-32P]-ATP. The reactions were run on a gel, transferred
to nitrocellulose, exposed for autoradiography and immunoblotted with
anti-SPF45 antibody. (D) COS-1 cells were transfected with empty
vector, Myc-SPF45 or Myc-SPF45-8A. Anti-Myc immunoprecipitates
were immunoblotted with anti-phospho-serine and anti-Myc antibodies.
Figure 6. Mutation of Clk1 phosphorylation sites on SPF45 regulates
SPF45 splice site utilization. (A) COS-1 cells were transfected for Fas
splicing assays as above using either Myc-SPF45, Myc-SPF45-8A or
Myc-SPF45-8D in the absence or presence of either empty vector or
Clk1. Twenty-four hour post-transfection, spliced products were
analysed by RT-PCR. A representative gel is shown. (B) The means
and SE for the relative ratios of exon 6 exclusion from (A) are shown
in the graph. Results were derived from three independent experiments
in duplicate and statistical significance (P< 0.01) is indicated. (C) The
same as in (A), but total RNA was subjected to RT-PCR analysis using
primers specific to Myc-SPF45 and GAPDH. (D) Protein lysates from
cells transfected in parallel were immunoblotted with anti-Myc and
anti-actin antibodies.
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Myc-SPF45-S222A and Myc-SPF45-S266A slightly, but
significantly, increased exon 6 exclusion (Figure 7B),
whereas Myc-SPF45-S202/204A decreased exon 6 exclu-
sion, which were consistent with the aforementioned
results. Collectively, these data indicate that Clk1 differ-
entially regulates SPF45 alternative splicing activity
through phosphorylation of different serines.
Mutation of the Clk1 phosphorylation sites on SPF45
affects Fas mRNA binding, but not association with other
splicing factors
SPF45 has been shown to associate with the splicing
factors SF3b155, U2AF65 and SF1 through residues in
its RRM domain (33,42). To determine whether SPF45
phosphorylation on the Clk1 sites altered binding to
these proteins, COS-1 cells were transfected with either
empty vector, Myc-SPF45, Myc-SPF45-8A or
Myc-SPF45-8D. Anti-Myc immunoprecipitates were
immunoblotted for endogenous splicing factors. All
three splicing factors bound equally well to Myc-SPF45
and either of the SPF45 mutants (Figure 8A), suggesting
that Clk1 phosphorylation of SPF45 does not significantly
affect association with these proteins. To determine
whether phosphorylation affected SPF45 binding to
Fas RNA, we performed RIP analysis on COS-1 cells,
which were cotransfected with Fas and wild-type or
mutant Myc-SPF45. The Fas mRNA detected in
anti-Myc immunoprecipitates was analysed by
qRT-PCR and was shown to specifically interact with
Myc-SPF45 (Figure 8B). Myc-SPF45-8A showed
enhanced binding to Fas mRNA, whereas Myc-SPF45-
8D showed reduced binding, with both reflecting the
relative changes in exon 6 exclusion observed in the
minigene splicing assays. These data suggest that SPF45
phosphorylation affects Fas mRNA binding.
SPF45 overexpression enhances cell migration and
invasion in a phosphorylation-dependent manner
We previously showed that SPF45 overexpression affects
cell proliferation and cell-matrix adhesion (21). To inves-
tigate the effect of SPF45 on cell motility, scratch wound
healing assays were performed on SKOV-3 cells stably
expressing Myc-SPF45, Myc-SPF45-8A, Myc-SPF45-8D
or empty vector. Equal expression of Myc-SPF45
Figure 7. Mutation of Clk1 phosphorylation sites in SPF45 differentially affects SPF45-indcuced exon 6 exclusion. (A and B) COS-1 cells were
transfected with plasmids for Fas (0.3 mg), wild-type (wt)-SPF45 (0.6 mg) or an SPF45 mutant (0.6 mg) as indicated. Twenty-four hour
post-transfection, spliced products were analysed by RT-PCR. The graph shows the relative ratios (short form to long form) of exon 6 exclusion.
The table under the graph indicates the means and SE for each SPF45 mutant. Results were derived from three independent experiments done in
duplicate. *P< 0.05 versus wt group, **P< 0.01 versus wt group. The bottom panels show western blotting of protein lyasates using anti-Myc and
anti-actin antibodies.
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proteins was observed in the stable cell lines
(Supplementary Figure S1). SPF45 and SPF45-8D signifi-
cantly increased cell migration compared with vector
control, whereas SPF45-8A did not (Figure 9A and B).
Similar results were observed in OV2008 stable cell lines
(Figure 9C and D). To confirm these results, we performed
transwell cell migration assays towards a 10% serum
chemoattractant. In SKOV-3 cells, SPF45 and
SPF45-8D overexpression significantly increased
serum-stimulated migration 2.1-fold and 2.2-fold, respect-
ively, compared with vector control cells, whereas
SPF45-8A inhibited cell migration by 41% (Figure 9E).
In OV2008 cells, SPF45 and SPF45-8D enhanced migra-
tion by 3.2-fold and 3.4-fold, respectively, compared with
vector control cells, whereas SPF45-8A had no effect
(Figure 9F).
In addition, we determined the effect of SPF45
overexpression on cell invasion through matrigel in a
transwell chamber. In SKOV-3 cells, SPF45 and
SPF45-8D significantly increased cell invasion by
1.9-fold and 2.1-fold, respectively, compared with vector
control cells, whereas 8A-SPF45 inhibited cell invasion by
45% (Figure 10A and C). In OV2008 cells, SPF45 and
SPF45-8D enhanced invasion by 3.2-fold and 3.5-fold, re-
spectively, whereas SPF45-8A did not significantly affect
invasion (Figure 10B and D). Collectively, these results
show that SPF45 overexpression promoted cell migration
and invasion in a phosphorylation-dependent manner.
SPF45 regulates fibronectin and cortactin in a
phosphorylation-dependent manner
Fibronectin enhances cell migration (43–46), and we pre-
viously showed that SPF45 overexpression enhanced
fibronectin expression in SKOV-3 cells in a manner inde-
pendent of SPF45 phosphorylation by MAP kinases (21).
Stable expression of SPF45 or SPF45-8D in SKOV-3 cells
increased fibronectin mRNA and protein expression,
whereas SPF45-8A expression completely inhibited
fibronectin expression (Figure 11A and B), indicating
that SPF45 regulates fibronectin expression in a Clk1
phosphorylation-dependent manner. In OV2008 cells,
SPF45 and SPF45-8D overexpression also increased
fibronectin protein levels compared with vector cell and
cells expressing SPF45-8A (Figure 11C).
Analysis of alternative splicing in SKOV-3-Myc-SPF45
cells identified the filamentous actin-binding protein
cortactin as a potential splicing target of SPF45
(Al-Ayoubi and Eblen, unpublished data). Cortactin
overexpression enhances cell migration and invasion
(47), whereas cortactin splice variant (SV) 1 induces less
migration and SV2 inhibits migration when overexpressed
(48). The qRT-PCR using primers specific to wt-cortactin
or total cortactin (wt+SV1+SV2) (Figure 12A) in the
SKOV-3 stable cell lines showed that SPF45 and
SPF45-8D significantly increased the ratio of wt:total
cortactin compared with vector control cells by 64 and
72%, respectively, whereas SPF45-8A did not show a sig-
nificant increase (Figure 12B). These differences were also
evident at the protein level (Figure 12C), where the
wt-cortactin doublet and faster migrating SV1, but not
SV2, were observed. In addition, expression of SPF45
and SPF45-8D enhanced ERK activation and phosphor-
ylation of Ser405 and Ser418 on cortactin (Figure 12C),
two ERK-dependent sites that enhance cortactin function
(39,49,50). Similar results were obtained in OV2008 stable
cell lines (Figure 12D and E).
DISCUSSION
We recently showed that ERK, JNK and p38 MAP
kinases phosphorylate SPF45 on a serine and threonine
residues, inhibiting Fas exon 6 exlusion and regulaing
the splicing and expression of fibronectin in a
phosphorylation-dependent and -independent manner, re-
spectively (21). In the present work, we show that Clk1
phosphorylates SPF45 in vitro on eight serine residues, all
of which are N-terminal to the RRM domain required for
splicing (33). Ser266 is in the G patch domain, and Ser288
and 291 are just C-terminal to this domain. All other
identified phosphorylation sites lie in the unstructured
N-terminal domain of unknown function (33). Clk1 phos-
phorylation of ASF/SF2, a physiological target, occurs on
serines in the arginine/serine dipeptide rich region of the
Figure 8. Mutation of the Clk1 phosphorylation sites in SPF45 affects
Fas mRNA binding, but not binding to other splicing factors.
(A) COS-1 cells were transfected with either empty vector,
Myc-SPF45, Myc-SPF45-8A or Myc-SPF45-8D. After 24 h, the cells
were lysed, and anti-Myc immunoprecipitates were run on a gel and
immunoblotted for Myc and co-immunoprecipitating endogenous
SF3b155, U2AF65 and SF1. Cell lysates (Lys.) were immunoblotted
as indicated. (B) COS-1 cells were co-transfected with Fas and
either empty vector, Myc-SPF45, Myc-SPF45-8A or Myc-SPF45-8D.
Twenty-four hour after transfection, the cells were subjected to RNA
IP using anti-Myc antibody followed by RT-qPCR analysis to detect
the binding of Fas mRNA to Myc-SPF45. Relative binding to the
control IP from six experiments are shown as mean±SE. *P< 0.05
versus vector group, #P< 0.05 versus wt-SPF45 group.
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protein (22,51). Clk1 prefers to phosphorylate serine
residues with a basic residue at the 3 and +3 position
(52), and many of the residues that we identified loosely fit
this consensus, with positively charged residues within
three residues of each side of the site of phosphorylation.
Clk1 expression enhanced SPF45 exon 6 exclusion from
Fas mRNA through multiple antagonistic mechanisms
involving both positive and negative regulation via direct
phosphorylation, negative regulation of RNA binding and
positive regulation of protein half-life (Figure 13).
Mutagenesis of all eight phosphorylation sites at once
showed that Clk1 phosphorylation inhibits SFP45-
induced exon 6 exclusion and Fas pre-mRNA binding,
whereas mutatagenesis of select groups of phosphoryl-
ation sites demonstrated positive or negative regulation
of splicing by individual sites; however, the effect of
Clk1 phosphorylation on SPF45 may vary when only
certain sites are phosphoryalted and may vary by RNA
target, as it is possible that only certain sites are
phosphorylated at a given time. In addition, it is
possible that other kinases also regulate phosphorylation
of one or more of these sites, as we have shown that MAP
kinases also phosphorylate SPF45 on Ser222 (21).
Clk1 expression enhanced the expression of
co-transfected SPF45, whereas inhibition of Clk1
through various means inhibited SPF45 expression and
exon 6 exclusion. The relative concentration of splicing
factors within the cell controls splice site utilization (11),
and our data showing that SPF45 induced exon 6 exclu-
sion in a dose-dependent manner support a role for
enhanced splicing of Fas mRNA partially occurring
through stabilization of SPF45 protein levels.
Mutational analysis of the Clk1 phosphorylation sites
did not identify a single or group of phosphorylation
sites that regulate SPF45 stability, suggesting that the
mechanism of protein stabilization is not through direct
phosphorylation of SPF45. Another study has shown that
Clk1 overexpression promoted SRp55 degradation via a
proteasome dependent pathway (53), whereas our data
demonstrate that Clk1 inhibits SPF45 proteosomal-
mediated degradation.
Phosphorylation of the RS domains of proteins regu-
lates their interactions with other proteins and with RNA
(15–17,54). We found that mutation of the Clk1 phos-
phorylation sites in SPF45 did not affect binding to
splicing factors SF1, SF3b155 and U2AF, which are
Figure 9. SPF45 overexpression enhances ovarian cancer cell migration in a phosphorylation site-specific manner. (A) SKOV-3 cell lines stably
expressing Myc-SPF45, Myc-SPF45-8A, Myc-SPF45-8D or empty vector were grown to confluence. Cells were pre-treated with mitomycin-C for 3 h
before being scratched and wound closure was recorded at 20 h by phase contrast microscopy. Representative images of six experiments are shown.
(B) Wound closure in (A) was calculated using Image J software and expressed as a percentage of the initial scratched area. Results shown are
mean±SE. *P< 0.05 versus vector group, #P< 0.05 versus wt-SPF45 group. (C and D) Scratch assays in OV2008 stable cells. The methods were the
same as in (A and B). (E and F) Transwell migration assays. Stable (E) SKOV-3 cells (2 104) or (F) OV2008 cells (5 104 cells) in 0.1% FBS were
added to the upper chamber, and 400ml of 10% FBS was added to the lower chamber of a transwell dish. After 24 h, non-migrating cells were
removed from the upper surface of the membrane, and the migrating cells were fixed with 4% paraformaldehyde and stained with 0.1% crystal
violet. Migrating cells were photographed and counted. Results from six experiments are shown as mean±SE. *P< 0.05 versus vector group,
#P< 0.05 versus wt-SPF45 group.
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known binding partners (33,42). Two regions of SPF45
that interact with these proteins are an RYF sequence
starting at R375 and charge interactions at N319
and E325 (33), all of which are C-terminal to our identified
sites. Mutations at the binding sites not only disrupt these
interactions but also SPF45 splicing of Fas pre-mRNA
(33). Our data showing that the SPF45 phosphorylation
mutants still regulate splicing of Fas further support that
these interactions are not affected by the identified phos-
phorylation sites. This suggests that these phosphorylation
sites regulate binding to other splicing proteins or may
regulate binding to RNA, and our data showed that
mutation of these phosphorylation sites affected binding
to Fas mRNA. A previous report showed that SPF45
binds to Sxl pre-mRNA in Drosophila (42); however,
whether SPF45 is capable of directly RNA binding was
questioned by Corsini et al. (33) who could not show
binding of SPF45 to an RNA oligonucleotide from the
b-thalassemic mutant b110 of the b-globin gene, a known
splicing target of SPF45 (42), and by virtue of the use of a
crosslinking reagent in the Sxl mRNA binding experi-
ment. In our study, we did not use a crosslinking agent.
Our data support a role for SPF45 phosphorylation in
RNA association, either direct or indirect, and correlate
with our results on alternative splicing of Fas, suggesting
this as a potential mechanism for regulation of SPF45
splicing by phosphorylation. If association with RNA
occurs through interactions with an unidentified binding
partner, it is likely that phosphorylation regulates associ-
ation with this protein.
Little is known about the biological function of SPF45
and how it is regulated by phosphorylation. SPF45 is
overexpressed in several human cancers (35) and was
correlated with a multidrug resistant phenotype (36). We
recently showed that SPF45 overexpression inhibits cell
proliferation and adhesion to fibronectin in a MAP
kinase phosphorylation-dependent manner (21). Our
current data show that SPF45 overexpression induces
cell migration and invasion in a manner dependent on
the identified Clk1 phosphorylation sites. In both assays,
Figure 10. SPF45 overexpression enhances ovarian cancer cell invasion in a phosphorylation site-specific manner. (A) Stable SKOV-3 cells (2 104)
and (B) OV2008 (5 104) cells in 0.5ml of 0.1% FBS were added to the top of a matrigel invasion chamber, with 0.75ml of 10% FBS in the lower
chamber. After 48 h, the non-invasive cells were removed from the upper surface of the membrane, and the invading cells were fixed with 4%
paraformaldehyde and stained with 0.1% crystal violet. Representative pictures of invading cells are shown. (C and D) Quantification of cell invasion
from (C) SKOV-3 and (D) OV2008 stable cell lines in (A and B) from six experiments are shown as mean±SE. *P< 0.05 versus vec group,
#P< 0.05 versus wt group.
Figure 11. SPF45 overexpression enhances fibronectin expression in a
phosphorylation site-specific manner. (A) Fibronectin mRNA expres-
sion was measured in stable SKOV-3 cells by qRT-PCR. Results from
six experiments are shown as mean±SE. *P< 0.05 versus vec group,
#P< 0.05 versus wt group. (B) Protein lysates from cells in (A) were
immunoblotted with anti-fibronectin (FN) and anti-actin antibodies.
(C) Fibronectin protein levels in OV2008 stable cell lines were
determined by immunoblotting as in (B).
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overexpression of a phospho-inhibitory mutant of SPF45
(SPF45-8A) acted as a null, with no increase in migration
and invasion compared with cells expressing empty vector,
whereas cells expressing SPF45-8D behaved similar to
wild-type SPF45. These data suggest a role for SPF45 in
cancer metastasis and that phosphorylation of these sites
control SPF45 biological functions. We identified two po-
tential mechanisms by which SPF45 may regulate these
processes: overexpression of fibronectin and splicing and
phosphorylation of cortactin. Fibronectin and its integrin
receptors increase cell migration and invasion in several
cell systems by various mechanisms (43–46). We have pre-
viously shown that SPF45 induces fibronectin expression
independent of phosphorylation by MAP kinases, but
now show that cells expressing SPF45-8A do not induce
fibronectin expression, suggesting that phosphorylation of
these sites regulates SPF45-induced fibronectin expression,
and that this may contribute to a lack of induction of
migration and invasion. SPF45 likely regulates a tran-
scription factor or pathway that enhances fibronectin
induction.
In addition, cortactin overexpression promotes cell mi-
gration and invasion through the regulation of actin poly-
merization in both lamellipodia and invadopodia (55).
There are three SVs of cortactin: wild-type, full-length
cortactin; SV1, which lacks the sixth cortactin repeat;
and SV2, which lacks the fifth and sixth repeats (48).
Overexpression of wild-type cortactin and, to a much
lesser extent, SV1, induce migration, whereas SV2
inhibits migration (48). We show that cells overexpressing
SPF45 or SPF45-8D have enhanced splicing of wild-type
cortactin relative to total cortactin (wt+SV1+SV2)
Figure 12. SPF45 overexpression inhibits alternative splicing of cortactin and enhanced phosphorylation of cortactin and ERK in a phosphorylation
site-dependent manner. (A) Schematic of cortactin alternative splicing, showing exon inclusion in wt cortactin and the two known SVs, representing
inclusion or exclusion of exons 10 and 11 (48). Arrows indicate the position of primers to detect total cortactin and wild-type (wt) cortactin.
(B) SPF45 and SPF45-8D enhance splicing of wild-type cortactin. Quantitative real-time PCR analysis of wild-type cortactin and total cortactin
(wt+SV1+SV2) from SKOV-3 cell lines stably overexpressing wt-SPF45, SPF45-8A, SPF45-8D or empty vector. The results, expressed as the ratio
of wt-cortactin to total cortactin, are from three experiments done in duplicate and are shown as mean±SE. *P< 0.05 versus vec group, #P< 0.05
versus wt-SPF45 group. (C) SPF45 and SPF45-8D overexpression enhance ERK activation and cortactin phosphorylation. Protein lysates from
SKOV-3 stable cell lines were immunoblotted for phosphorylated and total ERK and cortactin. S and L signify short and long exposure. (D) The
ratio of wild-type to total cortactin was measured in OV2008 stable cell lines as in (B). (E) Total and phosphorylated ERK and cortactin protein
were measured by immunoblotting OV2008 cell lysates as in (C). All immunoblots are representative images from three to four independent
experiments.
Figure 13. Clk1 regulates SPF45-induced exon 6 exclusion from fas
mRNA through antagonistic mechanisms. The model shows that Clk1
regulates SPF45 splice site utilization through multiple mechanisms
involving increases in SPF45 stability, phosphorylation and regulation
of mRNA binding. SPF45 overexpression causes enhanced migration
and invasion, dependent on the identified phosphorylation sites and
regulation of fibronectin and cortactin.
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compared with cells expressing SPF45-8A or empty
vector, suggesting that SFP45 regulates cortactin
splicing, dependent on these phosphorylation sites.
Our data show increased ERK activation in cells express-
ing SPF45 or SPF45-8D and a corresponding increase in
cortactin phosphorylation on serines 405 and 418. ERK
phosphorylation of cortactin at these sites (49) increases
cortactin-mediated actin polymerization via association
with N-WASP and activation of the Arp2/3 complex
(50) and increases cortactin localization to sites of
dynamic actin regulation, promoting increased duration
of lamellipodia formation (39).
In summary, our data establish novel roles for SPF45 in
the regulation of ovarian cancer cell migration and
invasion, two processes that are important for cancer me-
tastasis. In addition, we have demonstrated that these
roles are regulated by SPF45 phosphorylation by Clk1
and showed how these phosphorylations regulate SPF45
biochemical and biological functions.
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